-
1
-
-
47249153519
-
Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics
-
Feldmann M., Maini S.R. Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics. Immunol Rev 2008, 223:7-19.
-
(2008)
Immunol Rev
, vol.223
, pp. 7-19
-
-
Feldmann, M.1
Maini, S.R.2
-
2
-
-
0035306510
-
Uncoupling of inflammatory and destructive mechanisms in arthritis
-
van den Berg W.B. Uncoupling of inflammatory and destructive mechanisms in arthritis. Semin Arthritis Rheum 2001, 30:7-16.
-
(2001)
Semin Arthritis Rheum
, vol.30
, pp. 7-16
-
-
van den Berg, W.B.1
-
3
-
-
3442875303
-
Pathogenesis of bone and cartilage destruction in rheumatoid arthritis
-
Goldring S.R. Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology (Oxford) 2003, 42(Suppl 2):ii11-ii16.
-
(2003)
Rheumatology (Oxford)
, vol.42
, Issue.SUPPL. 2
-
-
Goldring, S.R.1
-
4
-
-
0023742630
-
Tumour necrosis factor in synovial exudates
-
Di Giovine F.S., Nuki G., Duff G.W. Tumour necrosis factor in synovial exudates. Ann Rheum Dis 1988, 47:768-772.
-
(1988)
Ann Rheum Dis
, vol.47
, pp. 768-772
-
-
Di Giovine, F.S.1
Nuki, G.2
Duff, G.W.3
-
5
-
-
0033524159
-
Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group
-
Maini R., St Clair E.W., Breedveld F., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932-1939.
-
(1999)
Lancet
, vol.354
, pp. 1932-1939
-
-
Maini, R.1
St Clair, E.W.2
Breedveld, F.3
-
6
-
-
79251471130
-
Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors
-
Mewar D., Wilson A.G. Treatment of rheumatoid arthritis with tumour necrosis factor inhibitors. Br J Pharmacol 2011, 162:785-791.
-
(2011)
Br J Pharmacol
, vol.162
, pp. 785-791
-
-
Mewar, D.1
Wilson, A.G.2
-
7
-
-
84855345966
-
-
PubMed.gov, US National Library of Medicine National Institutes of HealthUS National Library of Medicine National Institutes of Health, Accessed June 22, 2011
-
PubMed.gov, US National Library of Medicine National Institutes of HealthUS National Library of Medicine National Institutes of Health, Accessed June 22, 2011. http://www.ncbi.nlm.nih.gov/pubmed.
-
-
-
-
8
-
-
0010235710
-
This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999
-
Diagnostic Standards and Classification of Tuberculosis in Adults and Children
-
This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000, 161:1376-1395. Diagnostic Standards and Classification of Tuberculosis in Adults and Children.
-
(2000)
Am J Respir Crit Care Med
, vol.161
, pp. 1376-1395
-
-
-
12
-
-
0003484310
-
-
U.S. Food Drug Administration, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Washington, DC
-
Guidance for Industry, Bioanalytical Method Validation 2001, U.S. Food Drug Administration, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Washington, DC.
-
(2001)
Guidance for Industry, Bioanalytical Method Validation
-
-
-
13
-
-
0025363405
-
Spectral characteristics of heart rate variability before and during postural tilt. Relations to aging and risk of syncope
-
Lipsitz L.A., Mietus J., Moody G.B., Goldberger A.L. Spectral characteristics of heart rate variability before and during postural tilt. Relations to aging and risk of syncope. Circulation 1990, 81:1803-1810.
-
(1990)
Circulation
, vol.81
, pp. 1803-1810
-
-
Lipsitz, L.A.1
Mietus, J.2
Moody, G.B.3
Goldberger, A.L.4
-
15
-
-
0033975145
-
The pharmacokinetics of etanercept in healthy volunteers
-
Korth-Bradley J.M., Rubin A.S., Hanna R.K., et al. The pharmacokinetics of etanercept in healthy volunteers. Ann Pharmacother 2000, 34:161-164.
-
(2000)
Ann Pharmacother
, vol.34
, pp. 161-164
-
-
Korth-Bradley, J.M.1
Rubin, A.S.2
Hanna, R.K.3
-
16
-
-
33644990468
-
The comparability of etanercept pharmacokinetics in healthy Japanese and American subjects
-
Kawai S., Sekino H., Yamashita N., Tsuchiwata S., et al. The comparability of etanercept pharmacokinetics in healthy Japanese and American subjects. J Clin Pharmacol 2006, 46:418-423.
-
(2006)
J Clin Pharmacol
, vol.46
, pp. 418-423
-
-
Kawai, S.1
Sekino, H.2
Yamashita, N.3
Tsuchiwata, S.4
-
17
-
-
1942508209
-
Absence of a pharmacokinetic interaction between etanercept and warfarin
-
Zhou H., Patat A., Parks V., et al. Absence of a pharmacokinetic interaction between etanercept and warfarin. J Clin Pharmacol 2004, 44:543-550.
-
(2004)
J Clin Pharmacol
, vol.44
, pp. 543-550
-
-
Zhou, H.1
Patat, A.2
Parks, V.3
-
18
-
-
17644386569
-
Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein
-
Zhou H. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol 2005, 45:490-497.
-
(2005)
J Clin Pharmacol
, vol.45
, pp. 490-497
-
-
Zhou, H.1
-
19
-
-
0037384060
-
Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis
-
Lee H., Kimko H.C., Rogge M., et al. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther 2003, 73:348-365.
-
(2003)
Clin Pharmacol Ther
, vol.73
, pp. 348-365
-
-
Lee, H.1
Kimko, H.C.2
Rogge, M.3
|